



## **ADRB2** polymorphisms predict the risk of myocardial infarction and coronary artery disease

Dong-Wei Wang<sup>1</sup>, Min Liu<sup>1</sup>, Ping Wang<sup>1</sup>, Xiang Zhan<sup>1</sup>, Yu-Qing Liu<sup>1</sup> and Luo-Sha Zhao<sup>2</sup>

<sup>1</sup>*Department of Cardiology, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou, Henan, P.R. China.*

<sup>2</sup>*Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, P.R. China.*

### Abstract

Recently, the rs1042713 G > A and rs1042714 C > G polymorphisms in the beta-2 adrenergic receptor (ADRB2) gene were shown to be related to atherosclerosis diseases. Therefore, we performed a systemic meta-analysis to determine whether the two functional polymorphisms are related to the risk of myocardial infarction (MI) and coronary artery disease (CAD). We identified published studies that are relevant to our topic of interest. Seven case-control studies, with a total of 6,843 subjects, were incorporated into the current meta-analysis. Our analysis showed a higher frequency of rs1042713 G > A variant in patients with MI or CAD compared to healthy controls. A similar result was also obtained with the rs1042714 C > G variant under both the allele and dominant models. Ethnicity-stratified subgroup analysis suggested that the rs1042714 C > G variant correlated with an increased risk of the two diseases in both Asians and Caucasians, while rs1042713 G > A only contributes to the risk of two diseases in Asians. In the disease type-stratified subgroups, the frequencies of both the rs1042713 G > A and rs1042714 C > G variants were higher in the cases than in the controls in both the MI and CAD subgroups. Collectively, our data contribute towards understanding the correlation between the rs1042713 G > A and rs1042714 C > G polymorphisms in *ADRB2* and the susceptibility to MI and CAD.

**Keywords:** beta-2 adrenergic receptor, genetic polymorphism, myocardial infarction, coronary artery disease, meta-analysis.

Received: August 12, 2014; Accepted: April 27, 2015.

### Introduction

Coronary artery disease (CAD), the most common category of heart disease, is the leading cause of the hospital admissions, resulting in a high mortality in 2012 (Finegold *et al.*, 2013). CAD is induced by a plaque of fat, cholesterol and white blood cells that accumulate along the inner walls arteries of the heart, which narrows the arteries and reduces the rate and mass of blood flow to the heart (Korosoglou *et al.*, 2011). Myocardial infarction (MI), also referred to as acute myocardial infarction (AMI), accounts for the majority of the overall mortality in CAD (Korosoglou *et al.*, 2011). In 2010, over one million people in America experienced either their first or recurrent MI, and more than half of them died from it (Dupre *et al.*, 2012). During MI, patients gradually experience sudden chest pain beneath the thoracic cage and sometimes spreading to the left part of the neck or left arm. Additional symptoms include abnormal heartbeat, shortness of breath, feeling of in-

digestion, nausea or vomiting, sweating and anxiety (Kosuge *et al.*, 2006). The risk-related factors for MI include advanced age, a history of CAD, cigarette smoking, high serum concentrations of some lipids like triglycerides and low density lipoprotein cholesterol, decreased levels of high-density lipoprotein cholesterol, a lack of physical activity, heavy consumption of alcohol, intake of amphetamines and cocaine, and excess stress (Devlin and Henry, 2008; Graham *et al.*, 2007; Maclean, 2010). Genetic polymorphisms have recently been identified as an important risk factor in the pathology of CAD, including MI (Shea *et al.*, 2011; Tomaiuolo *et al.*, 2012).

The beta-2 adrenergic receptor (ADRB2) is a member of the superfamily of G-protein coupled receptors (GPCRs) (Cherezov *et al.*, 2007; Tchivileva *et al.*, 2010). The ADRB2 is widely expressed in most cell types, and it is the primary target of the catecholamine epinephrine during the stress response (Panebra *et al.*, 2010). ADRB2 signaling promotes cardiomyocyte survival and exerts sustained effects in the progenitor cells to regulate the differentiation, proliferation and mobility of the cells (Khan *et al.*, 2013). The *ADRB2* gene is located on the long arm of chromosome

Send correspondence to Luo-Sha Zhao. Department of Cardiology, the First Affiliated Hospital of Zhengzhou University, Jianshe Dong Road No. 1, 450007 Zhengzhou, P.R. China. E-mail: zhaoluosha628@163.com.

5q31-q32. Structurally, it is an intronless gene that encodes a 413 amino acid protein product (Neuman *et al.*, 1992; Ortega *et al.*, 2014). In recent years, several genetic polymorphisms have been identified in *ADRB2*, including rs1042713 G > A and rs1042714 C > G, and various studies have concentrated on the associations between these genetic polymorphisms and cardiovascular diseases (Li *et al.*, 2013; Zak *et al.*, 2008). *ADRB2* polymorphisms are relevant to several types of cardiovascular diseases, such as hypertension, heart failure, MI and CAD (Brodde, 2008; Kulminski *et al.*, 2010; Lou *et al.*, 2010). *ADRB2* activation regulates various biological functions, including the heart rate, blood pressure or respiration, and it may modulate the vasodilatation of the microcirculation in normal coronary arteries (Barbato *et al.*, 2005). The *ADRB2* plays an important modulatory role in the vasodilatation of human coronary arteries, and *ADRB2* polymorphisms have been reported to alter the functional responses of the receptor, which may lead to increased vasodilation and susceptibility to CAD (Barbato *et al.*, 2007). In addition, a previous study showed that *ADRB2* polymorphisms might elevate sympathetic nerve activity, which is associated with the increased risk of MI (Schurks *et al.*, 2009). On the one hand, there is abundant evidence supporting the notion that *ADRB2* polymorphisms correlate with an increased risk of MI and CAD (Barbato *et al.*, 2007; Jia *et al.*, 2010). On the other hand, some important studies report contrary results (Sala *et al.*, 2001; Wallerstedt *et al.*, 2005). The current meta-analysis reported herein used carefully selected and reliable data from published studies investigating the role of *ADRB2* polymorphisms in MI and CAD development.

## Materials and Methods

### Data sources and eligibility criteria

To identify all pertinent papers that assessed the correlations of *ADRB2* genetic polymorphisms with the susceptibility for MI and CAD, we comprehensively searched the PubMed, Embase, Web of Science, Cochrane Library, CINAHL, CBM and CNKI databases (last updated search in May 31<sup>st</sup>, 2014), utilizing selected common keywords for the *ADRB2* gene, polymorphism, MI and CAD. The following keywords were applied in our literature search: (“receptors, adrenergic, beta-2” or “receptors, adrenergic, beta-1” or “receptors, adrenergic, beta” or “adrenergic beta-2 receptors” or “beta 2 adrenergic receptor” or “beta-2 adrenergic receptor” or “beta2AR” or “ADRB2” or “beta2-AR” or “adrenergic beta-1 receptors” or “beta 1 adrenergic receptor” or “beta-1 adrenergic receptor” or “beta1AR” or “ADRB1” or “beta1-AR”) and (“polymorphism, genetic” or “polymorphism” or “polymorphisms” or “variants” or “SNP” or “mutation” or “genetic variants”) for the exposure factors, as well as (“MI” or “coronary artery disease” or “CAD” or “MI” or “myocardial infarct” or “myocardial infarction” or “myocardium infarction” or

“cardiac infarction” or “myocardia infarction” or “infarction myocardium” or “myocardial infarcted” or “heart infarction” or “heart infarction” or “MI” or “acute MI” or “CAD” or “CHD” or “AMI”). No restriction was set on the language of the article. We further scanned the bibliographies of the relevant articles manually to identify additional relevant papers. When the enrolled papers contained unclear or additional data in their original publications, the first authors were contacted and asked for clarification.

To enroll high-quality articles into the current meta-analysis, we searched case-control studies on genotypic data for *ADRB2* polymorphisms with human subjects with and without MI, or with and without CAD, that reported adjusted odd ratios (ORs) and 95% confidence intervals (CI). We only extracted studies that provided the sample number and sufficient information about the *ADRB2* variants, and we excluded articles with incomplete, unavailable or inappropriate data, as well as those studies in which MI and CAD were not confirmed by histopathologic examinations. In addition, only studies with a minimum of 100 cases were selected for the meta-analysis. All selected studies were consistent with Hardy-Weinberg equilibrium (HWE) in the control group. When 50% of the subjects in the extracted studies overlapped in more than two papers, we enrolled the most comprehensive study. Only the newest or most complete study was included when the same authors or group published the extracted studies.

### Study selection

Initially, a total of 243 articles were retrieved. During study selection, the titles and abstracts of the retrieved studies were screened based on the eligibility criteria detailed above, and 106 of the studies were excluded. Subsequently, the full texts of the remaining studies were carefully reviewed, and 103 studies failed to meet the eligibility criteria. Any ambiguities or disagreements on the eligibility for our meta-analysis were discussed to reach a final consensus among several reviewers. After stringent study selection, seven high-quality case-control studies were enrolled in the final analysis (Sala *et al.*, 2001; Wallerstedt *et al.*, 2005; Zee *et al.*, 2005; Abu-Amro *et al.*, 2006; Barbato *et al.*, 2007; Jia *et al.*, 2010; Yilmaz *et al.*, 2009). The studies had been conducted in China and Turkey (representing Asian populations), as well as in Belgium, Saudi Arabia, USA, Sweden and Italy (representing Caucasian populations). The sources of controls in our present meta-analysis were from population-based (PB) subjects. The genotyping methods detecting *ADRB2* polymorphisms included in this meta-analysis were TaqMan and polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analyses, and the *ADRB2* SNPs were rs1042714 C > G and rs1042713 G > A. All included studies, published between 2001 and 2010, were consistent with HWE (all  $p > 0.05$ ). The baseline characteristics of the extracted studies are presented in Table 1.

**Table 1** - Baseline characteristics of the studies included in the present meta-analysis.

First author	Year	Disease	Country	Sample size		Gender (M/F)		Age (years)		Genotyping methods	SNP	STROBE Score
				Case	Control	Case	Control	Case	Control			
Jia LX	2010	CAD	China	428	397	317/111	254/143	56 ± 10.6	53.2 ± 10.5	PCR-LDR	rs1042713 G > A	35
Yilmaz AK	2009	MI	Turkey	100	100	82/18	56/44	54.2 ± 11.9	51.4 ± 11.6	PCR-RFLP	rs1042713 G > A, rs1042714 C > G	23
Barbato E	2007	CAD	Belgium	570	216	399/171	110/106	65.0 ± 10.0	60.0 ± 13.0	TaqMan assay	rs1042713 G > A, rs1042714 C > G	36
Abu-Amro	2006	CAD	Saudi Arabia	773	895	477/296	519/376	53.8 ± 1.08	50.5 ± 3.6	PCR-CTPP	rs1042714 C > G	38
Zee RY	2005	MI	USA	523	2092	-	-	58.7 ± 0.4	58.8 ± 0.2	TaqMan assay	rs1042713 G > A, rs1042714 C > G	30
Wallerstedt SM	2005	MI	Sweden	174	342	129/52	253/89	57.0 ± 6.6	57.1 ± 6.6	TaqMan assay	rs1042713 G > A, rs1042714 C > G	28
Sala G	2001	MI	Italy	125	108	125/0	108/0	45	45	PCR-RFLP	rs1042713 G > A, rs1042714 C > G	27

M: male, F: female. PCR-LDR: polymerase chain reaction-ligase detection reaction. PCR-RFLP: polymerase chain reaction-restriction fragment length polymorphism. PCR-CTPP: polymerase chain reaction-confronting two-pair primers. SNP: Single nucleotide polymorphism. STROBE: Strengthening the Reporting of Observational Studies in Epidemiology. MI: myocardial infarction. CAD: coronary artery disease.

## Data extraction

To reduce a potential bias and enhance reliability, two investigators independently extracted information from the retrieved papers according to the selection criteria and, through discussion and reexamination, reached consensus on all items. The following relevant data were prospectively extracted from the eligible studies for final analysis: surname of the first author, year of publication, source of publication, study type, study design, sample size, age, sex, ethnicity and country of origin, genotyping method, source of controls, disease type, available genotype, genotype and variant frequencies, and HWE evidence in controls. All authors agreed to and approved the final selection of the studies that were included in the analysis.

## Quality assessment

The pairs of investigators involved in data extraction used the Strengthening the Reporting of Observational studies in Epidemiology (STROBE) quality score systems to independently assess the studies for quality (Vandenbroucke *et al.*, 2014). STROBE comprised 40 assessment items associated with the quality appraisal, with scores ranging from 0 to 40. According to the STROBE scores, the included studies were classified into the following three levels: low quality (0-19), moderate quality (20-29), and high quality (30-40), respectively. Any discrepancies, if present, with the STROBE scores of the enrolled publications were resolved by discussion with a third reviewer. The methodological quality of the extracted studies is also presented in Table 1.

## Statistical analysis

The OR was one measure of interest for assessing the relationship of the ADRB2 variants with MI and CAD. However, the OR value is influenced by sample size and/or differences in ethnic background. Theoretically, if there was no significant difference in the baseline data, the OR values could be directly used in our meta-analysis; otherwise, a pooled ORs (summary ORs) estimate was chosen to enhance stability of the final value. To calculate the effect size for each study, the summary ORs with the 95%CI were computed with the Z test. To provide quantitative evidence for all selected studies and minimize the variance of the summary ORs with the 95%CI, we conducted the current statistical meta-analyses with a random-effects model (DerSimonian and Laird method) or fixed-effects model (Mantel-Haenszel method) of the individual study results, under the situation in which data from independent studies could be combined. The random-effect model was applied when there was heterogeneity among the studies, while the fixed-effects model was applied when there was no statistical heterogeneity. The subgroup meta-analyses were also conducted according to ethnicity, disease type and genotyping method, so as to explore the potential effect modification, and the heterogeneity across the enrolled studies

was evaluated with the Cochran's  $Q$ -statistic ( $p < 0.05$  was considered statistically significant) (Jackson *et al.*, 2012). As a result of the low statistical power of the Cochran's  $Q$ -statistic, the  $I^2$  test was also measured to reflect the possibility of the heterogeneity between studies (Peters *et al.*, 2006). The  $I^2$  test values ranged from 0% (no heterogeneity) to 100% (maximal heterogeneity). We utilized univariate meta-regression analysis and multivariate meta-regression analysis to evaluate the possible sources of heterogeneity, and further multiple calibration tests were conducted using the Monte Carlo method. One-way sensitivity analysis was performed to evaluate whether the results could have been significantly affected. This was done through deleting a single study in our meta-analysis, one by one, to evaluate the influence of an individual data set on the pooled ORs. A funnel plot was constructed to assess the publication bias, which might affect the validity of the estimates. The symmetry of the funnel plot was further evaluated by Egger's linear regression test (Zintzaras and Ioannidis, 2005). All tests were two-sided, and a  $p$  value of  $< 0.05$  was considered statistically significant. STATA software, version 12.0 (Stata Corp, College Station, TX, USA) was used to ascertain the credibility and accuracy of these results.


## Results

### Association of *ADRB2* polymorphisms with MI and CAD

As shown in Figure 1, the major findings of the present meta-analysis included a higher frequency of the


rs1042713 G > A variant in the *ADRB2* of patients with MI or CAD compared to healthy controls (allele model: OR = 2.22, 95%CI: 1.12-4.38,  $p = 0.022$ ; dominant model: OR = 1.98, 95%CI: 1.22-3.21,  $p = 0.006$ ). At the same time, the results in Figure 1 suggested a positive association of the *ADRB2* rs1042714 C > G variant with the occurrence of MI or CAD (allele model: OR = 1.69, 95%CI: 1.24-2.31,  $p = 0.001$ ; dominant model: OR = 1.95, 95%CI: 1.28-2.97,  $p = 0.002$ ).

We observed differences in the association of rs1042713 G > A and rs1042714 C > G polymorphisms with MI or CAD among different ethnicities, disease types and genotyping methods, and further  $Q$ -test analysis revealed the presence of heterogeneity ( $I^2 > 90.5\%$ ,  $p < 0.05$ ). Therefore, we conducted subgroup analyses. The subgroup analysis based on ethnicity showed that the rs1042714 C > G polymorphism in the *ADRB2* was positively correlated to the risk of MI and CAD in both Asians and Caucasians (all  $p < 0.05$ ) (Figure 2). However, the subgroup analysis by ethnicity (Figure 2) showed a positive correlation between the *ADRB2* rs1042713 G > A variant and MI or CAD in Asians (allele model: OR = 3.73, 95%CI: 1.54-9.04,  $p = 0.004$ ), which was not the case for Caucasians ( $p = 0.125$ ). Simultaneously, subgroup analyses by disease type revealed that the frequencies of the *ADRB2* rs1042713 G > A and rs1042714 C > G polymorphisms were higher in the case groups than in the control groups in both the MI and CAD subgroups (all  $p < 0.05$ ) (Figure 2). A further subgroup analysis based on the genotyping method revealed that the rs1042714 C > G polymorphism in the *ADRB2* was positively correlated with MI and CAD in studies using



**Figure 1** - Forest plots of the influences of the *ADRB2* genetic polymorphism on the risk of myocardial infarction and coronary artery disease under the allele and dominant models.





**Figure 2** - Subgroup analyses for the influences of the *ADRB2* genetic polymorphism on the risk of myocardial infarction and coronary artery disease under the allele model.

Non-TaqMan assays (allele model: OR = 2.51, 95%CI: 1.51-4.18,  $p < 0.001$ ) instead of the TaqMan assay ( $p = 0.051$ ) (Figure 2). This subgroup analysis also revealed that the positive relationship with the *ADRB2* rs1042713 G > A variant was not associated with the susceptibility to MI or CAD, neither in the TaqMan, nor in the Non-TaqMan assay subgroup (both  $p > 0.05$ ). The ethnicity, disease type and genotyping method subgroup analyses under the other four models (dominant model, recessive model, homozygous model and heterozygous model) are shown in Table 2. Additionally, univariate meta-regression and multivariate meta-regression analyses demonstrated that the publication year, ethnicities, disease types and genotyping methods were not the main sources of heterogeneity among the included studies, and they were not the key factors influencing the overall results (all  $p > 0.05$ ), as shown in Table 3.

### Sensitivity analysis and publication bias

A sensitivity analysis was performed to evaluate whether the present meta-analysis was stable. Each study enrolled in our meta-analysis was individually evaluated for its effect on the pooled ORs. The overall statistical significance did not change when any single study was omitted. Therefore, the current meta-analysis data are relatively stable and credible (Figure 3). The graphical funnel plots of the seven studies for the *ADRB2* rs1042713 G > A and rs1042714 C > G variants were symmetrical, and Egger's test showed that there was no publication bias (all  $p > 0.05$ ) (Figure 4).

### Discussion

In our meta-analysis on correlations between the polymorphisms of rs1042713 (R16G) and rs1042714

**Table 2** - Meta-analysis of the correlations of *ADRB2* genetic polymorphisms with myocardial infarction and coronary artery disease.

Subgroup analysis	M allele vs. W (Allele model)			WM + MM vs. WW (Dominant model)			MM vs. WW + WM (Recessive model)			MM vs. WW (Homozygous model)			MM vs. WM (Heterozygous model)		
	OR	95%CI	p	OR	95%CI	p	OR	95%CI	p	OR	95%CI	p	OR	95%CI	p
rs1042713 G > A	2.22	1.12-4.38	0.022	1.98	1.22-3.21	0.006	4.31	1.26-14.7	0.020	4.75	1.39-16.2	0.013	3.93	1.12-13.7	0.032
Ethnicity															
Asians	3.73	1.54-9.04	0.004	3.10	2.19-4.39	<0.001	18.14	5.98-55.0	<0.001	22.15	11.63-42.	<0.001	14.98	3.06-73.3	0.001
Caucasians	1.73	0.86-3.46	0.125	1.64	0.94-2.87	0.080	2.38	0.83-6.82	0.107	2.63	0.87-7.90	0.085	2.18	0.77-6.16	0.140
Disease															
CAD	5.47	4.62-6.48	<0.001	3.45	2.77-4.28	<0.001	21.71	13.35-35.	<0.001	21.51	14.14-32.	<0.001	22.02	11.89-40.	<0.001
MI	1.35	1.03-1.75	0.028	1.41	1.04-1.91	0.028	1.43	0.93-2.18	0.101	1.72	1.00-2.93	0.048	1.22	0.88-1.70	0.235
Genotyping method															
Non-TaqMan assay	2.53	0.90-7.10	0.078	2.23	1.20-4.15	0.011	6.63	0.77-57.4	0.086	7.38	0.98-55.4	0.052	5.99	0.63-57.1	0.120
TaqMan assay	1.95	0.80-4.73	0.141	1.78	0.90-3.56	0.100	2.86	0.73-11.1	0.131	3.14	0.77-12.8	0.110	2.60	0.68-10.0	0.164
rs1042714 C > G	1.69	1.24-2.31	0.001	1.95	1.28-2.97	0.002	1.62	1.21-2.17	0.001	2.20	1.39-3.49	0.001	2.20	1.39-3.49	0.001
Ethnicity															
Asians	2.82	1.13-7.05	0.027	3.82	1.13-12.9	0.031	2.50	1.08-5.76	0.032	4.47	1.12-17.8	0.034	4.47	1.12-17.8	0.034
Caucasians	1.34	1.05-1.70	0.020	1.42	1.01-2.00	0.045	1.39	1.08-1.77	0.009	1.69	1.12-2.55	0.013	1.69	1.12-2.55	0.013
Disease															
MI	1.79	1.07-3.01	0.028	2.06	1.01-4.20	0.048	1.68	1.04-2.70	0.034	2.32	1.11-4.86	0.025	2.32	1.11-4.86	0.025
CAD	1.65	1.33-2.04	<0.001	1.96	1.58-2.44	<0.001	1.74	1.26-2.40	0.001	2.29	1.63-3.23	<0.001	2.29	1.63-3.32	<0.001
Genotyping method															
Non-TaqMan assay	2.51	1.51-4.18	<0.001	3.24	1.65-6.35	0.001	2.16	1.43-3.27	<0.001	3.67	1.75-7.69	0.001	3.67	1.75-7.69	0.001
TaqMan assay	1.20	1.00-1.45	0.051	1.24	0.93-1.64	0.142	1.32	1.05-1.66	0.020	1.51	1.02-2.23	0.040	1.51	1.02-2.23	0.040

W: wild-type allele, M: mutant allele, WW: wild-type homozygote, WM: heterozygote, MM: mutant homozygote, OR: odds ratio, 95%CI: 95% confidence interval, MI: myocardial infarction, CAD: coronary artery disease.

**Table 3** - Univariate and multivariate meta-regression analyses of potential source of heterogeneity.

Heterogeneity factors	rs1042713 G > A					rs1042714 C > G				
	Coefficient	SE	t	p	95%CI	Coefficient	SE	t	p	95%CI
Publication year										
Univariate	0.192	0.092	2.08	0.213	-0.064	0.242	0.218	1.11	0.059	-0.363
Multivariate	0.899	0.264	3.40	0.227	-2.458	0.636	0.059	10.82	0.051	-0.111
Ethnicity										
Univariate	0.750	0.750	1.00	0.211	-1.332	1.744	0.931	1.87	0.117	-0.840
Multivariate	-6.451	1.988	-3.25	0.232	-31.706	-2.565	0.360	-7.13	0.218	-7.136
Disease										
Univariate	1.604	0.260	6.17	0.936	0.882	-0.599	1.241	-0.48	0.126	-4.045
Multivariate	0.046	0.459	0.10	0.988	-5.789	-0.913	0.131	-6.95	0.225	-2.581
Genotyping method										
Univariate	0.182	0.784	0.23	0.191	-1.996	1.605	0.893	1.80	0.059	-0.874
Multivariate	3.587	1.086	3.30	0.232	-10.213	3.563	0.332	10.73	0.051	-0.655


SE: standard error. 95%CI: 95% confidence interval. UL: upper limit. LL: lower limit.

(Q27E) in the *ADRB2* with the susceptibility to MI and CAD based on available data, we found that the rs1042713 and rs1042714 polymorphisms are significantly associated with the susceptibility to MI and CAD. With its seven transmembrane segments, *ADRB2* belongs to the superfamily of G-protein-coupled adrenergic receptors, and it is an important target of endogenous ligands, such as catecholamine and epinephrine, that mediate stress responses in humans and animals (Schurks *et al.*, 2009; Yilmaz *et al.*, 2009; Litonjua *et al.*, 2010).

The *ADRB2* signaling cascade is of relevance in cardiovascular and metabolic diseases, including obesity, and also in mental disorders and asthma (Kushnir *et al.*, 2013). Additionally, accumulating evidence suggests that the *ADRB2* could participate in astrocyte homeostasis and neuroprotection through the metabolism of glycogen, immune response regulation, and neurotrophic factor release in response to neuronal injury. Conversely, *ADRB2* dysregulation may contribute to the development of Alzheimer's disease, stroke and hepatic encephalopathy (Laureys *et al.*, 2010). Furthermore, *ADRB2* signaling is involved in bronchoprotection and bronchodilation through mucociliary clearance, the accumulation of fluid and basophilic mediator release, all of which play essential roles in the development of asthma (Hizawa, 2009).

The development of cardiovascular diseases, such as MI and CAD, is thought to involve *ADRB2* through regulating the sympathetic and parasympathetic heart system influence on contractility and heart rate (Abu-Amro *et al.*, 2006). Moreover, the *ADRB2* could reduce atherosclerotic plaque cellularity through reducing vascular smooth muscle cell proliferation, an important feature of atherosclerotic lesion formation, leading to instability and rupture of the plaques and increasing the risk of MI and CAD (Piscione *et al.*, 2008). The *ADRB2* could also affect the vasodilatory function of vascular smooth muscle cells, leading to vasodilation and influencing the function and reactivity of cardiovascular cells (Wallerstedt *et al.*, 2005).

The two *ADRB2* polymorphisms, rs1042713 and rs1042714, are common in human populations and could lead to receptor alterations, affecting normal *ADRB* activity (Sala *et al.*, 2001). The rs1042713 and rs1042714 polymorphisms might also be related to agonists promoting desensitization and affecting hemodynamics and cardiac function (Cotarlan *et al.*, 2013). It has been reported that variants of the A/G site in rs1042713 have a strong relationship with CAD pathogenesis, and, in the dominant mode analysis, the low frequency of the A site in rs1042713 appears to be a key factor in CAD protection (<http://www.cqvip.com/qk/93060a/201008/35012429.html>). Abu-Amro *et al.* (2006) evaluated a Saudi Arabian sample and reported that the rs1042713 polymorphism may be an independent predictor of severe CAD, which is consistent with the findings of our meta-analysis. In addition, the Glu variant, compared to Gln in rs1042714, has been



**Figure 3** - Sensitivity analysis for the influences of the *ADRB2* genetic polymorphism on the risk of myocardial infarction and coronary artery disease under the allele and dominant models.


linked with vasodilatory responses to isoproterenol, which might be associated with atherosclerosis in cardiovascular diseases. One explanation could be that the Gln variant of rs1042714 results in a receptor with hyperactivity, leading to over-stimulation of catecholamine and over-activity of sympathetic nerves and, consequently, accelerating the development of coronary atherosclerosis (Barbato *et al.*, 2007). Zee *et al.* (2005), based on a US sample, reported that both of rs1042713 and rs1042714 polymorphisms are correlated with the development and progression of MI, which is also in line with our findings. Additionally, Heckbert *et al.* (2003) reported a possible relationship between the rs1042713 and rs1042714 polymorphisms in the *ADRB2* and a high risk of cardiovascular disease in the older age groups.

A stratified analysis, based on ethnicity and different disease types and detection methods, was performed to study the other influencing factors. A subgroup analysis based on ethnicity further showed that there were significant correlations between the rs1042713 and rs1042714 polymorphisms and the risk of MI and CAD. Our results are in agreement with other studies indicating that the rs1042713 and rs1042714 polymorphisms in the *ADRB2* gene have an intimate relationship with CAD and MI.

Hence, the *ADRB2* polymorphisms might be an important contributor to cardiovascular diseases, as well as an important genetic marker for the diagnosis and prognosis of cardiovascular diseases.

Our study has some limitations. First, a study performed in a Saudi Arabian population was included in the present meta-analysis, and the results of that study were in agreement with our overall results. However, Saudi Arabia is a multi-racial population, which may influence the validity of the overall results. Second, very few epidemiological studies have explored how the *ADRB2* gene is related to the susceptibility to MI or CAD, and most of the evidence that we gathered was from published composite coronary artery disease endpoints, including stroke, MI or CAD. This methodology may have restricted the extracted data. Third, all included studies had a case-control design; however, there were at least two apparent limitations. The sample size was relatively small, and the designed case-control studies always precluded causality. Therefore, it was difficult to reach a definitive conclusion. Fourth, with respect to the stratified analysis, there was a limitation in the subgroup analyses (ethnicity, disease, and genotyping method), and there was significant heterogeneity in some subgroups, restricting the overall interpretation of the





**Figure 4** - Funnel plot of publication biases on the relationships between the *ADRB2* genetic polymorphisms and the risk of myocardial infarction and coronary artery disease under the allele and dominant models.

pooled risk estimation. Finally, we only analyzed two *ADRB2* variants, excluding the potential influence of other variants within the pathway.

Despite the aforementioned limitations, our findings support that the rs1042713 and rs1042714 polymorphisms of the *ADRB2* gene have a strong correlation with, MI and CAD, when tested under both the allele and dominant models, particularly among Asians. This meta-analysis might serve as an anchoring point for designing further studies and developing *ADRB2*-based strategies to assess MI and CAD susceptibility.

## Acknowledgments

We would like to acknowledge the reviewer's helpful comments on this paper.

## References

- Abu-Amro KK, Al-Boudari OM, Mohamed GH and Dzimir N (2006) The Glu27 genotypes of the beta2-adrenergic receptor are predictors for severe coronary artery disease. *BMC Med Genet* 7:e31.
- Barbato E, Piscione F, Bartunek J, Galasso G, Cirillo P, De Luca G, Iaccarino G, De Bruyne B, Chiariello M and Wijns W (2005) Role of beta2 adrenergic receptors in human atherosclerotic coronary arteries. *Circulation* 111:288-294.
- Barbato E, Berger A, Delrue L, Van Durme F, Manoharan G, Boussy T, Heyndrickx GR, De Bruyne B, Ciampi Q, Vanderheyden M, *et al.* (2007) GLU-27 variant of beta2-adrenergic receptor polymorphisms is an independent risk factor for coronary atherosclerotic disease. *Atherosclerosis* 194:e80-86.
- Brodde OE (2008) Beta-1 and beta-2 adrenoceptor polymorphisms: Functional importance, impact on cardiovascular diseases and drug responses. *Pharmacol Ther* 117:1-29.
- Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, Choi HJ, Kuhn P, Weis WI, Kobilka BK, *et al.* (2007) High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. *Science* 318:1258-1265.
- Cotarlan V, Brofferio A, Gerhard GS, Chu X and Shirani J (2013) Impact of beta(1)- and beta(2)-adrenergic receptor gene single nucleotide polymorphisms on heart rate response to metoprolol prior to coronary computed tomographic angiography. *Am J Cardiol* 111:661-666.
- Devlin RJ and Henry JA (2008) Clinical review: Major consequences of illicit drug consumption. *Crit Care* 12:202.
- Dupre ME, George LK, Liu G and Peterson ED (2012) The cumulative effect of unemployment on risks for acute myocardial infarction. *Arch Intern Med* 172:1731-1737.
- Finegold JA, Asaria P and Francis DP (2013) Mortality from ischaemic heart disease by country, region, and age: Statistics from World Health Organisation and United Nations. *Int J Cardiol* 168:934-945.
- Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, Dallongeville J, De Backer G, Ebrahim S, Gjelsvik B, *et al.* (2007). European guidelines on cardiovascular disease prevention in clinical practice: Executive summary: Fourth

- Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). *Eur Heart J* 28:2375-2414.
- Heckbert SR, Hindorff LA, Edwards KL, Psaty BM, Lumley T, Siscovick DS, Tang Z, Durda JP, Kronmal RA and Tracy RP (2003) Beta2-adrenergic receptor polymorphisms and risk of incident cardiovascular events in the elderly. *Circulation* 107:2021-2024.
- Hizawa N (2009) Beta-2 adrenergic receptor genetic polymorphisms and asthma. *J Clin Pharm Ther* 34:631-643.
- Jackson D, White IR and Riley RD (2012) Quantifying the impact of between-study heterogeneity in multivariate meta-analyses. *Stat Med* 31:3805-3820.
- Jia LX, Li JN, Bian YF, Liu GZ and Xiao CS (2010) Correlation of ADRB2 with coronary artery disease in Shanxi Han population. *Chin J Integr Med Cardio-/Cerebrovasc Dis* 8:911-912.
- Khan M, Mohsin S, Avitabile D, Siddiqi S, Nguyen J, Wallach K, Quijada P, McGregor M, Gude N, Alvarez R, *et al.* (2013) Beta-Adrenergic regulation of cardiac progenitor cell death vs. survival and proliferation. *Circ Res* 112:476-486.
- Korosoglou G, Lehrke S, Mueller D, Hosch W, Kauczor HU, Humpert PM, Giannitsis E and Katus HA (2011) Determinants of troponin release in patients with stable coronary artery disease: Insights from CT angiography characteristics of atherosclerotic plaque. *Heart* 97:823-831.
- Kosuge M, Kimura K, Ishikawa T, Ebina T, Hibi K, Tsukahara K, Kanna M, Iwahashi N, Okuda J, Nozawa N, *et al.* (2006) Differences between men and women in terms of clinical features of ST-segment elevation acute myocardial infarction. *Circ J* 70:222-226.
- Kulminski AM, Culminskaya IV, Ukraintseva SV, Arbeev KG, Akushevich I, Land KC and Yashin AI (2010) Polymorphisms in the ACE and ADRB2 genes and risks of aging-associated phenotypes: The case of myocardial infarction. *Rejuvenation Res* 13:13-21.
- Kushnir VM, Cassell B, Gyawali CP, Newberry RD, Kibe P, Nix BD, Sabzpoushan A, Kanuri ND and Sayuk GS (2013) Genetic variation in the beta-2 adrenergic receptor (ADRB2) predicts functional gastrointestinal diagnoses and poorer health-related quality of life. *Aliment Pharmacol Ther* 38:313-323.
- Laureys G, Clinckers R, Gerlo S, Spooren A, Wilczak N, Kooijman R, Smolders I, Michotte Y and De Keyser J (2010) Astrocytic beta(2)-adrenergic receptors: From physiology to pathology. *Prog Neurobiol* 91:189-199.
- Li ZG, Wu H, Zhou YL, Chen ZJ, Meng JX, Yang JQ, Chen JY and Zhong SL (2013) Association of beta-adrenergic receptor genes polymorphisms with incidence of subsequent cardiovascular events in Han Chinese patients with coronary artery disease. *Chin Med J (Engl)* 126:4679-4684.
- Litonjua AA, Gong L, Duan QL, Shin J, Moore MJ, Weiss ST, Johnson JA, Klein TE and Altman RB (2010) Very important pharmacogene summary ADRB2. *Pharmacogenet Genomics* 20:64-69.
- Lou Y, Liu J, Huang Y, Liu J, Wang Z, Liu Y, Li Z, Li Y, Xie Y and Wen S (2010) A46G and C79G polymorphisms in the beta2-adrenergic receptor gene (ADRB2) and essential hypertension risk: A meta-analysis. *Hypertens Res* 33:1114-1123.
- Maclean A (2010) The things they carry: Combat, disability and unemployment among US men. *Am Sociol Rev* 75:563-585.
- Neuman WL, Le Beau MM, Farber RA, Lindgren V and Westbrook CA (1992) Somatic cell hybrid mapping of human chromosome band 5q31: A region important to hematopoiesis. *Cytogenet Cell Genet* 61:103-106.
- Ortega VE, Hawkins GA, Moore WC, Hastie AT, Ampleford EJ, Busse WW, Castro M, Chardon D, Erzurum SC, Israel E, *et al.* (2014). Effect of rare variants in ADRB2 on risk of severe exacerbations and symptom control during longacting beta agonist treatment in a multiethnic asthma population: A genetic study. *Lancet Respir Med* 2:204-213.
- Panebra A, Wang WC, Malone MM, Pitter DR, Weiss ST, Hawkins GA and Liggett SB (2010) Common ADRB2 haplotypes derived from 26 polymorphic sites direct beta2-adrenergic receptor expression and regulation phenotypes. *PLoS One* 5:e11819.
- Peters JL, Sutton AJ, Jones DR, Abrams KR and Rushton L (2006) Comparison of two methods to detect publication bias in meta-analysis. *JAMA* 295:676-680.
- Piscione F, Iaccarino G, Galasso G, Cipolletta E, Rao MA, Brevette G, Piccolo R, Trimarco B and Chiariello M (2008) Effects of Ile164 polymorphism of beta2-adrenergic receptor gene on coronary artery disease. *J Am Coll Cardiol* 52:1381-1388.
- Sala G, Di Castelnuovo A, Cuomo L, Gattone M, Giannuzzi P, Iacoviello L and De Blasi A (2001) The E27 beta2-adrenergic receptor polymorphism reduces the risk of myocardial infarction in dyslipidemic young males. *Thromb Haemost* 85:231-233.
- Schurks M, Kurth T, Ridker PM, Buring JE and Zee RY (2009). Association between polymorphisms in the beta2-adrenergic receptor gene with myocardial infarction and ischaemic stroke in women. *Thromb Haemost* 101:351-358.
- Shea J, Agarwala V, Philippakis AA, Maguire J, Banks E, Depristo M, Thomson B, Guiducci C, Onofrio RC, Kathiresan S, *et al.* (2011) Comparing strategies to fine-map the association of common SNPs at chromosome 9p21 with type 2 diabetes and myocardial infarction. *Nat Genet* 43:801-805.
- Tchivileva IE, Lim PF, Smith SB, Slade GD, Diatchenko L, McLean SA and Maixner W (2010) Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: A randomized, double-blind, placebo-controlled, crossover pilot study. *Pharmacogenet Genomics* 20:239-248.
- Tomaiuolo R, Bellia C, Caruso A, Di Fiore R, Quaranta S, Noto D, Cefalu AB, Di Micco P, Zarrilli F, Castaldo G, *et al.* (2012) Prothrombotic gene variants as risk factors of acute myocardial infarction in young women. *J Transl Med* 10:235.
- Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M and for the SI (2014) Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and elaboration. *Int J Surg* 12:1500-24.
- Wallerstedt SM, Eriksson AL, Ohlsson C and Hedner T (2005) Haplotype association analysis of the polymorphisms Arg16Gly and Gln27Glu of the adrenergic beta2 receptor in a Swedish hypertensive population. *J Hum Hypertens* 19:705-708.

- Yilmaz A, Kaya MG, Merdanoglu U, Ergun MA, Cengel A and Menevse S (2009) Association of beta-1 and beta-2 adrenergic receptor gene polymorphisms with myocardial infarction. *J Clin Lab Anal* 23:237-243.
- Zak I, Sarecka-Hujar B and Krauze J (2008) Cigarette smoking, carrier state of A or G allele of 46A > G and 79C > G polymorphisms of beta2-adrenergic receptor gene, and the risk of coronary artery disease. *Kardiol Pol* 66:380-386; discussion 387.
- Zee RY, Cook NR, Reynolds R, Cheng S and Ridker PM (2005) Haplotype analysis of the beta2 adrenergic receptor gene and risk of myocardial infarction in humans. *Genetics* 169:1583-1587.
- Zintzaras E and Ioannidis JP (2005). HEGESMA: Genome search meta-analysis and heterogeneity testing. *Bioinformatics* 21:3672-3673.

*Associate Editor: Maria Rita Passos-Bueno*

License information: This is an open-access article distributed under the terms of the Creative Commons Attribution License (type CC-BY), which permits unrestricted use, distribution and reproduction in any medium, provided the original article is properly cited.